Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.

Thorac Cancer · 2022 · PMC8807266 · PMID 34958168

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, our results also showed that patients in subgroups of both sexes, bone or brain metastasis and exon 19 del or exon 21 L858R mutation showed a trend of longer PFS in the IO+C group (Supporting Information, Figure S1).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.